BACKGROUND: Rigorous guideline development methods are designed to produce recommendations that are relevant to common clinical situations and consistent with evidence and expert understanding, thereby promoting guidelines' acceptability to providers. No studies have examined whether this technical quality consistently leads to acceptability.
INTRODUCTION
Physicians have been slow to incorporate clinical guidelines into their decision making because of 3 basic reasons: lack of knowledge about guidelines, barriers to guideline implementation, and unfavorable attitudes toward guidelines. [1] [2] [3] [4] [5] Among unfavorable attitudes, arguably the two most fundamental include physicians believing that a specific guideline does not apply to their patients and their questioning a guideline's interpretation of the evidence (i.e., its validity). If physicians question a guideline's relevance or validity, they may not even consider other issues. Other well-established unfavorable attitudes include believing that the recommendations do not appear cost-effective, lacking confidence in developers, and lacking self-efficacy or motivation. [6] [7] [8] Some guidelines are viewed unfavorably by very few physicians (1%), whereas others are viewed unfavorably by the majority (91%). Some physicians find no guidelines acceptable. 6 In part to increase the likelihood that providers will view guidelines favorably, 9 experts have established formal development and evaluation standards, the most widely accepted of which is the "Appraisal of Guidelines Research and Evaluation" Instrument (AGREE). [10] [11] [12] [13] [14] National Guidelines Clearinghouse requires basic standards. 15 Nevertheless, empirical research has not examined whether rigorous developmenti.e., good technical quality-consistently produces guidelines that providers find acceptable.
In 2004, legislation in California provided a compelling reason to consider this issue: it required the workers' compensation system to adopt a guideline for utilization management and mandated a systematic evaluation of guidelines. [16] [17] [18] But would a guideline selected on the basis of technical quality ensure a favorable reception among providers who treat occupational disorders? One purpose of this study, sponsored by the California Department of Industrial Relations, was to answer this question. We identified promising guidelines for musculoskeletal disorders and appraised them using AGREE. Our objective was to assess the clinical acceptability of each guideline-i.e., providers' views about how useful each guideline would be in clinical practice. We examined the 2 fundamental dimensions mentioned above: whether providers experienced in caring for musculoskeletal disorders believe that the guidelines applied to common clinical situations (perceived comprehensiveness) and whether they agree with the guidelines' interpretations of the evidence (perceived validity) (defined below).
We chose an expert panel method because it enabled us to compare the acceptability of individual guidelines, ensuring that the providers had detailed knowledge of the guidelines and generally favorable attitudes toward guidelines (so that any low ratings would reflect perceived flaws in individual guidelines rather than generally unfavorable attitudes). Also, using a multidisciplinary expert panel and well-established panel methods might yield a more reliable, 19 informative, and nuanced evaluation than alternative methods, such as focus groups or a survey of community providers. Because we sought to assess clinical acceptability rather than to establish objective validity or determine the reliability of guideline development methods, panelists assessed guidelines' recommendations and embedded literature summaries as community providers do, basing judgments on their own knowledge and experience rather than on an independent literature review.
METHODS
We searched for guidelines covering musculoskeletal disorders, selected guidelines meeting inclusion criteria, and assessed technical quality. We then developed and applied a method for assessing clinical acceptability. A detailed report is available online at http://www.rand.org/publications/MG/ MG400/. 20 
Identifying and Selecting Guidelines
We searched MEDLINE and National Guidelines Clearinghouse using keywords covering musculoskeletal disorders, surveyed specialty society web sites, interviewed workers' compensation experts, and contacted state governments. Next, we applied inclusion criteria addressing technical quality, scope, and cost (Table 1) . Of 73 documents identified, 20 some were not guidelines and many did not cover multiple tests and therapies, were out of date, or lacked an updating plan. Two specialty society guidelines and 3 proprietary utilization management guidelines met all inclusion criteria (Table 2) . 
Appraising Technical Quality
For these 5 guidelines, we evaluated technical quality using AGREE, which assesses the resources and processes used to develop guidelines via 6 domains (Table 3 ) having 2 to 7 questions each.
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Internationally, AGREE is the preferred tool for assessing guidelines and its reliability has been demonstrated. [11] [12] [13] 21 However, its validity remains unproved, 12, 22 and it does not assess guideline content or the underlying evidence. 12, 13, 23 A question within AGREE's rigor-of-development domain stipulates that independent, external reviews by both clinical and methodological experts should be performed, but it does not specify what such reviews should entail.
AGREE is supported by detailed instructions; training is not required. 24 At least 2 raters but preferably 4 raters are needed.
We had a physician with a Ph.D. in health services research and an author of a paper on guideline quality rate AGREE questions using guideline content, developers' answers, and corroborating evidence. 30 The AGREE method creates standardized domain scores from individual ratings, incorporating any variability into overall scores.

Appraising Clinical Acceptability
We evaluated the guidelines' acceptability to expert providers, considering 2 dimensions not included in AGREE: perceived comprehensiveness and perceived validity. 11 A multidisciplinary panel rated guidelines in a 2-round, modified Delphi process derived from the RAND/UCLA Appropriateness Method, 25 which has been shown to be moderately reliable and to have predictive validity. 26, 27 Separate panels examining the same clinical topics have yielded similar conclusions (κ =0.51-0.83). 28 Panel judgments about the appropriateness of Surgery have predicted results of subsequent randomized trials, 29 and
process-oriented quality measures developed using this method have been positively associated with patient outcomes. 30 This panel included: 1 Internal Medicine physician, 2 occupational medicine physicians, 1 physiatrist, 1 physical therapist, 1 neurologist board-certified in pain management, 2 doctors of chiropractic, 2 orthopedic surgeons, and 1 neurosurgeon. We contacted relevant specialty societies seeking leaders with experience treating workers and practicing at least 20% of their time, then chose panelists from diverse locations and practice settings who self-reported having favorable attitudes toward guidelines and extensive experience in guideline development or implementation.
Next, we specified the content panelists would evaluate within the guidelines: appropriateness and quantity of care for common and costly therapies. Specifying appropriateness is part of the definition of a guideline; 9 quantity was required by the legislation. [16] [17] [18] Appropriate care meant potential benefits to individual patients exceeded risks irrespective of cost, inappropriate care meant risks to patients exceeded potential benefits, and care of uncertain appropriateness was between the two. Quantity meant frequency, intensity, and duration of therapy.
To give the evaluation depth and breadth, we selected 10 condition/therapy pairs that were common and costly in the California workers' compensation system (Table 4) . 31 Considering appropriateness of care for each condition/therapy pair and, when relevant, quantity of care, yielded 16 topics to rate. An occupational medicine physician and a registered nurse annotated guideline booklets to identify relevant content. Because we were unable to include all common and costly tests and therapies, we asked panelists to rate any residual content (i.e., content within each guideline other than the 16 topics) and each guideline overall. For each of the 16 topics, any residual content, and each guideline overall, panelists rated perceived comprehensiveness and perceived validity. Comprehensive meant panelists believed that the guideline addressed appropriateness or quantity for most workers with the condition who might be considered candidates for the therapy. For the residual and overall ratings, comprehensive meant the guideline addressed most of the common and costly tests and therapies used in treating occupational disorders. Valid meant that recommendations regarding appropriateness or quantity were consistent with panelists' interpretations of existing evidence or, in the absence of higher quality evidence, their expert opinions.
Panelists rated guidelines independently during the first round then met in person to discuss areas of disagreement and rerate during the second round. For both rounds, panelists received instructions, planned interpretation methods, annotated guideline booklets, and unblinded electronic access to the guidelines. Using private, equally weighted ballots (our report contains samples), 20 panelists rated perceived comprehensiveness and perceived validity separately on 9-point scales with 9 as the highest.
During the 1-day second round in October 2004, panelists received AGREE results and the first-round ratings, including the distribution and panelists' own ratings relative to the distribution. An experienced moderator led the discussions of the 16 topics, any residual content, and each guideline overall. At the conclusion of each discussion, panelists rerated the guidelines. We used a modified Delphi method, rather than a consensus method that forces agreement, to allow different attitudes to be expressed and contend with one another and true agreement or disagreement to emerge. Panelists wrote comments on ballots and made closing statements.
We interpreted ratings as follows: a median rating of 7 to 9 without disagreement = comprehensive or valid (depending on which was being rated); a median rating of 1 to 3 without disagreement = not comprehensive or not valid; a median rating of 4 to 6 or any rating with disagreement = intermediate comprehensiveness or uncertain validity. We defined disagreement as follows: 4 or more panelists rated the guideline in the 1 to 3 range and 4 or more in the 7 to 9 range. In sensitivity analyses, we discarded the single highest and lowest ratings to determine whether outliers affected the results. 25 For this paper, we summarized perceived comprehensiveness and perceived validity results across the 16 topics by determining the fraction and percent of topics in each interpretation category. We assumed that developers had not intended guidelines to cover topics that panelists judged to be not comprehensive.
RESULTS
Appraising Technical Quality
AGREE scores were generally high (Table 3) . Regarding scope and purpose, each guideline had a well-articulated objective clinical questions and target population. RAND appraisers felt that recommendations were usually presented clearly. Rigorof-development scores were high because developers clearly described the methods used to search for evidence and formulate recommendations.
Uninvolved individuals reviewed all 5 guidelines before publication. American Academy of Orthopedic Surgeons members reviewed AAOS. ACOEM developers described the review as extensive but provided no detail. A distinct unit within the parent company reviewed Intracorp. Various community and academic providers reviewed McKesson. Affiliates of specialty societies and typical end-users reviewed ODG. No developers reported whether clinical and methodological experts were included.
Relative weaknesses included the following. Stakeholder involvement scores were variable when developers did not clearly describe patient involvement or pilot testing. Three applicability scores were low because developers discussed few details about costs, implementation barriers, or criteria for monitoring adherence. Regarding editorial independence, 1 guideline (Intracorp) discussed potential development members' conflicts of interest in limited detail.
Appraising Clinical Acceptability
To summarize (Table 5) , panelists felt that Intracorp was most comprehensive but invalid. Panelists judged the other 4 guidelines to be moderately comprehensive and valid. Regarding perceived comprehensiveness, panelists frequently felt that the guidelines discussed therapies without defining appropriateness or quantity of care for most workers with the condition. Panelists judged all 5 guidelines to be of intermediate comprehensiveness overall. Of the 16 appropriateness and quantity topics that the panelists rated, Intracorp covered all 16 and was judged comprehensive for 69% of them. The other 4 guidelines covered fewer topics and were judged comprehensive for 50% to 60% of the ones they did cover.
Regarding perceived validity, panelists often found guidelines' statements to be only somewhat consistent with their understandings of the literature and opinions. Overall, AAOS and ACOEM were considered valid, McKesson and ODG were of uncertain validity, and Intracorp was not valid. Despite higher overall ratings for AAOS and ACOEM, these guidelines were valid for 40% and 50% of the topics they covered, respectively, whereas McKesson and ODG were valid for 43% and 36%, respectively. For Intracorp, 31% of covered topics were not valid and 6% were valid. Tables 6 and 7 of the Appendix list perceived comprehensiveness and perceived validity by topic. Sensitivity testing did not affect results.
Two panelists' ballot comments expound upon the Intracorp ratings: "proscriptive", "poor documentation of validity", "no evidence provided", "inconsistent", "too restrictive", and "all conditions treated similarly". In the closing statements, 7 panelists commented that all 5 guidelines were barely satisfactory. As a group, the panelists were generally uncomfortable with the "proscriptive" nature of the proprietary guidelines compared with the specialty society guidelines.
DISCUSSION
We found that 5 major guidelines covering musculoskeletal disorders all performed extremely well on most technical quality standards-far better than many guidelines do. 10, 30, 32 Given the exceptional resources and processes used in their development, one would expect providers with especially favorable attitudes toward guidelines and extensive clinical knowledge to find these guidelines acceptable. However, our multidisciplinary expert panel found the best of them barely adequate and the worst invalid. Panelists thought that these guidelines neglected common clinical situations, and recommendations often diverged from panelists' interpretations of the literature and experience.
If sufficient development resources and processes do not ensure that guidelines are acceptable to providers, then a mechanism for evaluating this outcome of guideline development is needed. Drawing an analogy between assuring the quality of guidelines and assuring the quality of medical care, a framework for guideline evaluation can be borrowed from the Donabedian model. [33] [34] [35] [36] "Structure" would include resources such as the developer's identity, participating providers' qualifications, and the strength of available literature. "Process" would represent the methods for communicating with stakeholders, searching the literature, formulating recommendations, and considering implementation issues. The ultimate outcome would be whether the target population's health improved after guideline implementation. 2 Adherence by providers would represent an intermediate outcome, and specific reasons for nonadherence would be more proximate intermediate outcomes. 6 The most proximate outcomes would be each recommendation's alignment with the best evidence available. 13, 22 Existing evaluation methods address the structure and process of guideline development and assume-erroneouslythat favorable outcomes will result. 10, 11, 14 For example, having a well-defined scope and purpose should produce recommendations that providers find applicable to common clinical situations. Yet our panelists felt that none of the guidelines comprehensively covered one of the most common treatments Lastly, the variable AGREE scores for stakeholder involvement and applicability suggest that developers could have done more to increase acceptability to providers. Several guideline evaluators, including AGREE authors, have argued that, in addition to being appraised for technical quality, all guidelines should be independently reviewed by clinical experts. However, given our findings, the mere performance of an external review appears insufficient to ensure clinical acceptability. Specific goals and methods for performing clinical reviews have not been established yet, 11, 14, 37 and they appear to be needed.
Clinical appraisals of an individual guideline should have 2 goals: assessing providers' attitudes toward the guideline and identifying potential barriers to implementation. 6 Ideally, such appraisals should be structured enough to produce scientifically sound and reliable results, and detailed enough to identify problems with particular topics. The method we used could serve as an initial test of providers' attitudes toward guidelines. Studies should evaluate its reliability in this application, performance for other conditions and for individual guideline recommendations, and its ability to predict guideline acceptance by community providers. Our evaluation touched on 3 attitudes (perceived comprehensiveness, perceived validity, and confidence in developer); future appraisals should address others. Guideline developers should also assess providers' perceptions of implementation barriers because these perceptions are strongly associated with actual implementation. [38] [39] [40] [41] An instrument for assessing implementation barriers has been published. 42 In this study, several limitations could have influenced the relationship between technical quality and clinical acceptability. Including more guidelines would have permitted a quantitative assessment of this relationship, but we examined guidelines that exhibited little variability in technical quality, i.e., the guidelines that providers would be most likely to find acceptable. The fact that panelists judged one not valid is remarkable. AGREE could be insensitive to differences between well-developed guidelines, and it does not evaluate the underlying evidence or how developers conduct systematic literature reviews. Published evidence is less developed for musculoskeletal disorders than some conditions. Our panelists assessed perceived validity rather than comparing guideline recommendations against a synthesis of evidence, as others have done, 22 but the latter would not reflect how providers examine guidelines in actual practice where the guidelines themselves must persuade readers of their validity. Attitudes toward individual guidelines vary greatly, and these findings might not apply to other conditions. Some panel physicians were unfamiliar with chiropractic manipulation of the extremities. Our panel method has not been validated for this application, and experts' opinions may differ from those of community providers. Our inclusion criteria selected both clinical and utilization management guidelines. Although AGREE was not developed to assess the latter, its questions appear relevant. Panelists could have held biases against utilization management guidelines, but concealing developer identities would not have resolved this because the guidelines designed to limit utilization were obvious. Panelists rejected only one such guideline, highlighting its greater discrepancy between technical quality and clinical acceptability.
Nevertheless, our study indicates that rigorous development methods do not consistently produce guidelines that are acceptable to providers, which would likely limit the guidelines' usefulness and, ultimately, their ability to improve care. During guideline development, developers should do more to involve stakeholders and consider implementation issues. Before guideline dissemination, clinical acceptability should be independently and formally evaluated. The content pertaining to these topics was judged not comprehensive and, therefore, on the assumption that the guideline was not intended to cover those topics, validity judgments are not applicable.
